pioglitazone has been researched along with Depressive Disorder, Treatment-Resistant in 1 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Depressive Disorder, Treatment-Resistant: Failure to respond to two or more trials of antidepressant monotherapy or failure to respond to four or more trials of different antidepressant therapies. (Campbell's Psychiatric Dictionary, 9th ed.)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Robakis, TK | 1 |
| Watson-Lin, K | 1 |
| Wroolie, TE | 1 |
| Myoraku, A | 1 |
| Nasca, C | 1 |
| Bigio, B | 1 |
| McEwen, B | 1 |
| Rasgon, NL | 1 |
1 other study available for pioglitazone and Depressive Disorder, Treatment-Resistant
| Article | Year |
|---|---|
Early life adversity blunts responses to pioglitazone in depressed, overweight adults.
Topics: Adult; Adverse Childhood Experiences; Antidepressive Agents; Child; Depressive Disorder, Treatment-R | 2019 |